Donald Egan

Discovery and Preclinical Profile of Saxagliptin (BMS-477118):  A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

David J. Augeri, Jeffrey A. Robl, David A. Betebenner et al. · Journal of Medicinal Chemistry · 2005 · 617 citations · Full text

Selective thyroid hormone receptor-β activation: A strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability

Gary J. Grover, Karin Mellström, Ye Liu et al. · Proceedings of the National Academy of Sciences · 2003 · 222 citations · Full text

Effects of the Thyroid Hormone Receptor Agonist GC-1 on Metabolic Rate and Cholesterol in Rats and Primates: Selective Actions Relative to 3,5,3′-Triiodo-<scp>l</scp>-Thyronine

Gary J. Grover, Donald Egan, Paul G. Sleph et al. · Endocrinology · 2004 · 162 citations · Full text

Metabolic Rate, Obesity, Molecular Pharmacology +20

<i>N</i>-Aryl-oxazolidin-2-imine Muscle Selective Androgen Receptor Modulators Enhance Potency through Pharmacophore Reorientation

Alexandra A. Nirschl, Yan Zou, Stanley R. Krystek et al. · Journal of Medicinal Chemistry · 2009 · 29 citations · Full text

Pharmaceutical Science, Gut Ph, Pharmacotherapy +16

The Dual Peroxisome Proliferator-Activated Receptor α/γ Activator Muraglitazar Prevents the Natural Progression of Diabetes in db/db Mice

Effie Tozzo, Randolph Ponticiello, Joann Swartz et al. · Journal of Pharmacology and Experimental Therapeutics · 2007 · 17 citations